Christian Grohé - Researcher Profile

Publications

3 shown

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi , Julien Mazières , David Planchard +27 more

2015 The Lancet Oncology 1406 citations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

2019 The Lancet 2014 citations

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu , Masahiro Tsuboi , Jie He +21 more

In patients with stage IB to IIIA <i>EGFR</i> mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who r...

2020 New England Journal of Medicine 1609 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 5,029
Institution: Evangelische Lungenklinik Berlin

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-2724-7647

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.